Molecular hierarchy of mammary differentiation yields refined markers of mammary stem cells by Dos Santos,  C. O. et al.
Molecular hierarchy of mammary differentiation yields
reﬁned markers of mammary stem cells
Camila O. dos Santosa,1, Clare Rebbecka, Elena Rozhkovaa, Amy Valentinea, Abigail Samuelsa,b, Lolahon R. Kadiric,
Pavel Ostenc, Elena Y. Harrisd,2, Philip J. Urend, Andrew D. Smithd, and Gregory J. Hannona,1
aHoward Hughes Medical Institute, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; bArts and Science Undergraduate Program, Vanderbilt
University, Nashville, TN 37212; cCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; and dMolecular and Computational Biology, University of
Southern California, Los Angeles, CA 90089
This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2012.
Contributed by Gregory J. Hannon, March 11, 2013 (sent for review December 28, 2012)
The partial puriﬁcation of mouse mammary gland stem cells (MaSCs)
using combinatorial cell surface markers (Lin−CD24+CD29hCD49fh)
has improved our understanding of their role in normal develop-
ment and breast tumorigenesis. Despite the signiﬁcant improve-
ment in MaSC enrichment, there is presently no methodology that
adequately isolates pure MaSCs. Seeking new markers of MaSCs,
we characterized the stem-like properties and expression signa-
ture of label-retaining cells from the mammary gland of mice
expressing a controllable H2b-GFP transgene. In this system, the
transgene expression can be repressed in a doxycycline-dependent
fashion, allowing isolation of slowly dividing cells with retained
nuclear GFP signal. Here, we show that H2b-GFPh cells reside
within the predicted MaSC compartment and display greater
mammary reconstitution unit frequency compared with H2b-
GFPneg MaSCs. According to their transcriptome proﬁle, H2b-GFPh
MaSCs are enriched for pathways thought to play important roles
in adult stem cells. We found Cd1d, a glycoprotein expressed on
the surface of antigen-presenting cells, to be highly expressed by
H2b-GFPh MaSCs, and isolation of Cd1d+ MaSCs further improved
the mammary reconstitution unit enrichment frequency to nearly
a single-cell level. Additionally, we functionally characterized a set
of MaSC-enriched genes, discovering factors controlling MaSC sur-
vival. Collectively, our data provide tools for isolating a more pre-
cisely deﬁned population of MaSCs and point to potentially critical
factors for MaSC maintenance.
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The murine mammary gland resembles, to some extent, thehuman mammary gland in development, milk production,
and progression to carcinogenesis, making it an ideal system to
develop methodologies and form hypotheses of relevance to
women. The use of cell surface markers to isolate selected cell
types from mice has greatly enhanced our understanding of de-
velopment and our knowledge of molecular pathways and inter-
actions that inﬂuence it. Mammary gland stem cells (MaSCs) have
commanded attention because of not only their roles in the cycles
of gland morphogenesis but also their potential contribution in
tumor initiation. Full characterization of MaSCs, however, has
been hampered by their scarcity. Enrichment of the MaSC com-
partment has, until now, been achieved by using a combination of
cell surface markers (Lin−CD24+CD29hCD49fh) (1, 2). Thus far,
these cells have been enriched to 1 MaSC per every 64 cells
stained Lin−CD24+CD29h (1). This is sufﬁcient to test for MaSC
repopulation capacity and to some extent, roles in tumorigenesis,
but this level of purity is less suitable for more complex molecular
analyses that deﬁne MaSCs and their properties.
Additional characterization of MaSCs has been achieved using
a transgenic mouse model expressingGFP under the control of the
s-ship promoter (3). This gene is expressed in embryonic and he-
matopoietic stem cells but not differentiated cells (4). GFP+ cells in
this mouse model were shown to reside at the tips of the terminal
end buds, where MaSCs are believed to be located in these
developing mammary gland structures (3, 5). Transplantation of
the MaSC-enriched GFP+CD49fh cells improved the mammary
reconstitution unit (MRU) frequency to 1/48 cells, an increase over
the previous shown frequency for CD24+CD29hCD49fh cells. Al-
though being very elegantly performed and enhancing our un-
derstanding of MaSC localization, studies with this mouse model
did not achieve a greater enrichment for MaSCs using more con-
veniently accessible markers, such as cell surface proteins.
Given the limitations in accurately purifying MaSCs, we sought
to devise a method better suited for identifying this population.
Here, we describe the use of long-term label retention to increase
the MRU frequency within MaSC-enriched CD24+CD29h cells.
This approach, previously applied to the isolation of skin stem
cells (6), enables the identiﬁcation of slowly dividing cells, a
characteristic of adult stem cells. To mark slowly dividing cells,
expression of the H2b histone, linked to GFP, is regulated by a
tetracycline responsive element (TRE) and a tet-controlled
transcription activator (tTA) under the endogenous keratin K5
promoter (K5tTA-H2b-GFP). In the absence of tetracycline or its
analog doxycycline (DOX), the tTA binds to TRE and activates
transcription of H2b-GFP. Treatment with DOX prevents the
tTA binding to TRE, and transcription of H2b-GFP is terminated
(6). As the cell divides, newly synthesized, unlabeled H2b replaces
the H2b-GFP; therefore, the more slowly dividing cells will retain
GFP expression for an extended period.
We were able to improve the MaSC enrichment by isolating
GFP-retaining cells after a long-term inhibition of transgene
expression. We refer to these cells as H2b-GFPh MaSCs (CD24+
CD29hH2b-GFPh). Comparisons between expression proﬁles of
all mammary gland cell types suggested that H2b-GFPh MaSCs
differentially expressed several genes involved in pathways pre-
viously described as playing roles in other adult stem cells. Ad-
ditional analysis of the H2b-GFPh MaSC expression signature
led to the identiﬁcation of a cell surface marker that, combined
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with conventional markers, resulted in the isolation of an MaSC
population with an elevated proportion of MRUs. In addition,
we performed a focused shRNA screen, targeting genes that
were differentially expressed in our newly characterized MaSC-
enriched cell population, revealing potential regulators of mam-
mary gland biogenesis. Overall, this work improves our ability to
purify MaSCs and provides valuable insights into their role in
mammary gland development and perhaps, even tumor initiation.
Results
H2b-GFP Label-Retaining Cells Enrich for MaSCs. To better enrich for
the MaSC population, we assessed the feasibility of using mam-
mary gland label-retaining cells to select for MaSCs, given that
a slower division rate is an excepted characteristic of adult stem
cells. We adopted a system wherein expression of the H2b his-
tone, linked to GFP, is regulated by a TRE and a tTA under the
endogenous keratin K5 promoter K5tTA-H2b-GFP (a gift from
Elaine Fuchs, Rockefeller University, New York, NY). Keratin
K5 is expressed in cells of the basal compartment, the region
considered to be home to MaSCs (7). This system displays some
advantages over the previous gene reporter-based methods used
to isolate MaSCs, because it takes advantage of one of the more
general properties of stem cells: their relative quiescence. In
support of the use of this mouse model, there were previous hints
that MaSC-enriched CD24+CD29h cells display BrdU label-
retaining properties (1), although label-retaining populations
were not functionally characterized.
Initial experiments using the H2b-GFP mice assessed the ex-
pression and distribution of GFP-positive cells in the adult
mammary gland (Fig. 1A). Histological sections revealed the
presence of several GFP+ cells located within structures re-
sembling the mammary gland ductal epithelium (Fig. 1B and Fig.
S1A,Upper). Treatment of H2b-GFP mice with DOX over a 12-wk
period, thus ceasing transcription of H2b-GFP transgene, dra-
matically reduced the number of cells expressing GFP. Notably,
those cells that remained GFP+ were located at the tips of the
terminal end buds. These distinct sites in the ductal epithelium
are the areas currently believed to be resident by MaSCs (8) (Fig.
1C and Fig. S1A, Lower).
To compliment this observation, under the hypothesis that
mammary gland label-retaining cells comprise a population of
potential MaSCs, we investigated the correlation between GFP
retention and expression of previously deﬁned MaSC-enriched
cell surface markers, CD24 and CD29. Using FACS analysis, we
were able to subdivide the mammary gland (after depletion
of endothelial and hematopoietic cells as shown in Fig. S1B) into
three distinct cell compartments: luminal (CD24hCD29+), oc-
cupied by luminal cells; basal (CD24+CD29h), occupied by
myoepithelial cells and MaSCs; and stromal (CD24−CD29+) (1)
(Fig. 1D, Upper Left). The majority of GFP+ cells from a trans-
genic H2b-GFP mouse off DOX could be categorized into either
basal or stromal compartments, with far fewer GFP+ cells oc-
cupying the luminal compartment (Fig. 1D, Upper Right and Fig.
S1C, Left). After a 12-wk DOX chase, the overall proportion
of GFP+ cells decreased by more than one-half, and the
presence of a GFP+ luminal compartment was all but elimi-
nated (Fig. 1D, Lower Left and Fig. S1C, Center). Focusing on
GFP intensity (a measure that directly relates to the rate of cell
division), selection of only the brightest GFP+ cells (GFPh)
resulted in a greater proportion remaining in the CD24+CD29h
basal compartment, whereas the stromal compartment was sig-
niﬁcantly reduced after GFPdim cells were removed (Fig. 1D,
Lower Right and Fig. S1C, Right). This result suggests that the
most label-retaining cells reside within the basal compart-
ment and may represent the MaSCs population.
The beneﬁt of using GFP to test for label retention, as op-
posed to BrdU, is that its detection does not require ﬁxation and
staining. We were then able to test the biological differences,
using mammary gland transplants, between GFPh cells (H2b-
GFPh MaSCs) and GFP− cells (H2b-GFP− MaSCs) within the
MaSC-enriched compartment. Transplantation assays are a fun-
damental criterion to evaluate stemness and have been used
previously for several tissues, including the mammary gland (1, 2, 9).
For these experiments, the inguinal glands were removed from
the endogenous tissue of prepubescent females before injection
of donor cells. Donor cells were harvested from mammary glands
of H2b-GFP mice after a 12-wk DOX chase, dissociated, lineage-
depleted, and sorted according to GFP intensity (Fig. S1D). Cells
(GFPh and GFP−) were then injected, and outgrowths from
donor cells were compared (by visualization of GFP+ epithe-
lium) 12 wk posttransplantation. Given that the recipient animals
are not treated with DOX, all cells derived from the donor mice
will resume expression of the H2b-GFP transgene and give rise
to GFP+ outgrows. MRU frequency was estimated according
to the previously described algorithm (10). Transplantation of
500 H2b-GFPh MaSCs (n = 5) gave rise to GFP+ epithelium in
all injected glands. This ability to reconstitute was still retained
when only 50 cells were transplanted (Fig. 1E). In contrast, only
one-half of the glands injected with 500 H2b-GFP− MaSCs dis-
played ﬂuorescent outgrowths, decreasing to just 29% with in-
jection of 50 cells (Dataset S1). These results represent an
increase in the estimated frequency ofMRUs from1/70 cells, when
MaSC selection was performed using CD24+CD29h alone (1), to
1/33 cells, with restriction to H2b-GFPh cells to further deﬁne
MaSCs. Comparatively, the MRU frequency among H2b-GFP−
MaSCs was estimated to be 1/149 (Dataset S1). Colony-forming
ability was also twofold greater for H2b-GFPh MaSCs when 500 of
these cells were seeded in aMatrigel (BD Bioscience) and cultured
for 7 d (Fig. S1E).
Considered together, these data suggest that mammary gland
H2b-GFPh label-retaining cells represent a subset, if not an entire
population, of the MaSCs. Our experiments using a repressible
H2b-GFP transgene have built on previous knowledge regarding
the label-retaining properties of stem cells in the mammary gland
and conﬁrmed that MaSC CD24+CD29h cells reside mainly
within the H2b-GFPh label-retaining cell population. In addition
to these experiments, we also found that hormone-dependent
activation of MaSC proliferation and differentiation, triggered
by one complete cycle of pregnancy and involution in transgenic
H2b-GFP mice treated with DOX, completely depleted GFP+
cells, validating that H2b-GFPh cells truly represent a population
of slowly dividing cells rather than being a transgenic artifact.
It has been proposed that MaSCs comprise less than 5% of the
total basal compartment. Our ﬁndings support this notion given
that we ﬁnd label-retaining H2b-GFPh cells to account for ∼0.2%
of the total CD24+CD29h population (Fig. S1D,Upper Right). We
also compared the distribution of H2b-GFPh–retaining cells with
expression of a recently identiﬁed marker for myoepithelial
progenitor-like cells, CD61. This marker was expressed by most of
the H2b-GFPdim population, whereas virtually all H2b-GFPh cells
were negative for CD61 staining, suggesting perhaps a unique
mammary gland cell differentiation pattern, where H2b-GFPh la-
bel-retaining cells might occupy the top of hierarchy.
H2b-GFP Cells Display a Stem Cell-Like Expression Signature. Having
established that H2b-GFPh MaSCs have reconstitution properties,
we next sought to determine where these cells fall in the mammary
differentiation hierarchy with regard to their gene expression pat-
terns. Using a combination of cell surface markers (1, 11), six dis-
tinct cell types were isolated by FACS to a purity of >90%: H2b-
GFP MaSCs (Lin−CD24+CD29hH2b-GFPhCD61−), myoepithelial
progenitor-like cells (Lin-CD24+CD29hH2b-GFP−/lCD61+),
myoepithelial differentiated cells (Lin−CD24+CD29hH2b-GFP−
CD61−), luminal progenitor cells (Lin−CD24hCD29+CD61+
CD133−), luminal ductal cells (Lin−CD24hCD29+CD61−CD133+),
and luminal alveolar cells (Lin−CD24hCD29+CD61− CD133−)
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(Fig. 2A). The myoepithelial progenitor-like cells were deﬁned
by expression of CD61 as a positive cell surface marker and their
positioning as the second most label-retaining cell population.
Hierarchical clustering of combined RNAseq replicates split
mammary gland cells into two main branches: the basal com-
partment, comprising myoepithelial progenitor cells, myoepithe-
lial differentiated cells, and H2b-GFP MaSCs, and the luminal
compartment, with luminal progenitor cells and differentiated
cells (Fig. 2B). As predicted by prior characterization of MaSCs
(1), we found the expression proﬁle of H2b-GFP MaSCs to be
more closely related to the expression proﬁle of myoepithelial cells
than luminal cells; however, H2b-GFP MaSCs were still an out-
group compared with other cells in this cluster. Analysis over all
mammary gland cell types yielded several hundred genes differ-
entially expressed among all cell types (Fig. 2B), spanning diverse
gene ontology groups and pathways (Dataset S2). More speciﬁ-
cally, genes differentially expressed in H2b-GFP MaSCs were
enriched in G protein-coupled receptors and pathways involving
Wnt/B-catenin signaling, areas previously described to play fun-
damental roles in other adult stem cells (12). Differential
Fig. 1. H2b-GFP label-retaining cells represent a population of MaSCs. (A) Experimental scheme. Mammary glands were harvested from K5tTa-H2b-GFP
transgenic mice either off (GFP pulse) or on DOX diet (GFP chase) and further processed for immunological staining or single-cell suspension FACS sorting. (B and
C) Tissue histology H2b-GFP+ cells distribution. Mammary glands from transgenic mice off and on DOX diet were harvested, defatted, embedded in agarose, and
imaged with two-photon microscopy. (B) Mice off DOX diet (GFP pulse) showing a broad distribution of GFP+ cells in mammary gland ductal structures. (C) After
a 12-wk DOX chase, H2b-GFP+ label-retaining cells became restricted to the edges of the ductal structures. (D) Flow cytometry proﬁle of H2B-GFP+ cells. Upper Left
shows the proﬁle of a lineage-depleted (CD45−, Ter119−, and CD31−) nontransgenic mammary gland according to CD24 and CD29 staining and highlights the
three cell compartments: luminal (CD24hCD29+; comprising luminal progenitor cells, luminal alveolar cells, and luminal ductal cells); basal (CD24+CD29h; com-
prising myoepithelial progenitor cells, myoepithelial differentiated cells, and MaSCs); and stromal. Total GFP+ cells from H2b-GFP transgenic mice off DOX diet
(GFP pulse mice; Upper Right) displayed a similar cellular compartmental distribution with fewer luminal-type cells. The CD24CD29 cell proﬁle of H2b-GFP+ cells
from GFP chase mice (on DOX) were analyzed using two strategies to deﬁne GFP-expressing cells. Lower Left displays CD24CD29 staining of total H2b-GFP+ cells,
whereas Lower Right shows the CD24CD29 staining of H2b-GFPh cells. The focus on GFPh cells, the most label-retaining cells, drastically decreased the cellular
content of all mammary gland compartments and retained a greater proportion of cells inside of the basal compartment, potentially representing MaSCs. (E)
Histological analysis of mammary gland H2b-GFPh MaSCs outgrowths. Cleared fat pads from prepubescent female mice were injected with either total H2b-GFP−
MaSCs (CD24+CD29hGFP− cells) or H2b-GFPh MaSCs (CD24+CD29hGFPhcells), harvested 12 wk after transplantation, embedded in agarose, stained with antibodies,
and imaged on a Zeiss 710 LSM (Zeiss) confocal microscope. Images display outgrowths of two distinct glands injected with H2b-GFPh MaSCs.



















expression patterns were conﬁrmed on four genes by performing
quantitative RT-PCR on H2b-GFP MaSCs (n = 4 individually
sorted samples) and myoepithelial progenitor cells (n = 3 in-
dividually sorted samples) (Fig. S2). mRNA for the Cd24 and
Cd29 genes was quantiﬁed as control, because all myoepithelial
cells displayed similar levels of expression for these genes.
These results further conﬁrmed that mammary cell types could
be differentiated based on their gene expression proﬁles, allowing
us to use these proﬁles to select cell type-speciﬁc genetic identiﬁers.
Additional Cell Surface Marker to Improve MaSCs Puriﬁcation. Be-
cause of limitations on the ability to purify MaSCs to homoge-
neity based on currently used cell surface markers, we searched
for new surface markers that might identify MaSCs using the
RNAseq data. We ﬁrst generated a list of ∼500 genes that en-
code for cell surface markers according to their gene ontology
term function (e.g., basolateral membrane, cell surface, mem-
brane protein, or basement membrane). This list was further
reduced to genes with high expression levels for the MaSC H2b-
GFP cells. Five candidate cell surface proteins came out of this
analysis (Fig. S3A): CD1d, a glycoprotein expressed on the sur-
face of various mouse and human antigen-presenting cells (13);
Cd59a, a regulator of the membrane attack complex (14); CD22,
a regulatory lectin involved in repressing hyperactivation of the
immune system (15); CD93, a C-type lectin involved in cell–cell
adhesion processes (16); and CD74, an HLA class II protein,
part of the major histocompatibility complex (17). Antibodies
against CD1d, CD59a, and CD22 positively stained a distinct
population of cells contained within the Lin-MaSC CD24+
CD29h cells (Fig. 3A), whereas antibodies against the proteins,
CD93 and CD74, failed to stain any mammary gland cells. We
further tested CD1d MaSCs (CD24+CD29hCD1d+), CD59a
MaSCs (CD24+CD29hCD59ah), and CD22 MaSCs (CD24+
CD29hCD22+) for their ability to grow colonies in Matrigel cul-
ture. Two populations, CD1d MaSCs and CD59ah MaSCs [rep-
resenting 1% and 4%, respectively, of the total MaSC (CD24+
CD29h) population], displayed an approximately twofold increase
in colony-forming ability compared with the total MaSCs pop-
ulation (Fig. S3B). However, we found CD1d MaSCs to have a
greater colony-forming ability compared with CD59ah MaSCs,
with one-half as many cells needed to produce the same number
of colonies (200 and 500 cells, respectively, seeded on Matrigel).
Additional analysis showed that all CD1d+ cells from the MaSC-
enriched CD24+CD29h population were also CD59ah, whereas
the remaining majority of CD59a+ cells from the MaSC-enriched
CD24+CD29h population was negative for CD1d expression (Fig.
3B). Based on the enhanced colony-forming abilities of CD1d
MaSCs over CD59ah MaSCs and the overlap of the two markers
within the CD1d+ populations, we decided to pursue the experi-
ments using CD1d as an MaSC marker.
We next sorted CD1d+ MaSCs for RNAseq and compared
their gene expression proﬁle with those cell populations de-
scribed in Fig. 2. Cluster analysis of all RNAseq libraries suggests
that the CD1d MaSC expression signature is closer to the ex-
pression pattern found for H2b-GFP MaSCs than for any other
cell type (Fig. S3C). These results could be suggestive that the
common expression signature between CD1d+ MaSCs and H2b-
GFPh MaSCs deﬁnes the stem cell state of mammary gland cells.
To ask whether CD1d+ MaSCs are slowly dividing cells, we
performed BrdU label retention experiments. We injected BrdU
into eight prepubescence female mice (3 wk old) over 5 consec-
utive d. Cells were harvested on the day of the last injection (week 0)
from one-half of the mice and after 12 wk from the remaining mice
(Fig. 3C). FACS analysis showed that ∼20% of the total MaSC
population retained BrdU, and up to 60% of CD1d MaSCs were
BrdU-retentive. This result adds conﬁdence to the use of CD1d as
a cell surface marker to represent the H2b-GFPMaSCs, because it
is the most label-retaining cells and perhaps, therefore, the most
enriched for stem-like cells within the mammary gland.
We then went on to repeat the mammary gland reconstruction
assays, but this time, we compared CD1d+MaSC transplantation
efﬁciency with the transplantation efﬁciency displayed by the
total MaSC (Lin−CD24+CD29h) population using cells from the
H2b-GFP mice off DOX. Comparing donor-derived outgrowths
(identiﬁable by GFP expression) between injection with CD1d+
MaSCs and injection with total MaSCs, we found that, despite
bringing the injected cell number down to single digits, CD1d+
MaSCs effectively gave rise to GFP outgrowths in the majority of
graft recipients (Fig. 3D and Dataset S3). This result gave a pre-
dicted MRU frequency of ∼1/8 CD1d MaSCs compared with the
1/44 MRU frequency from total MaSCs (Dataset S3). FACS
collection of CD1d+ MaSCs from a reconstructed gland also ef-
fectively gave rise to a gland when serially transplanted into an-
other mouse, showing that these cells also have the capacity to
self-renew in addition to regenerating the gland (Fig. 3E).
MaSC-Focused shRNA Screen. To identify genes and pathways
necessary for the maintenance of MaSC reconstitution potential,
we selected a set of abundantly and differentially expressed genes
from RNAseq libraries of H2b-GFPh MaSCs and CD1d+ MaSCs
and targeted them in shRNA-mediated knockdown experiments.
We used shRNAs identiﬁed by a prediction algorithm developed
in our laboratory, taking, on average, two hairpins per gene.
Hairpins targeting nondifferentially expressed genes were also
included as well as depletion control hairpins targeting Rpa3 and
Polr2b and neutral control hairpins targeting Fireﬂy luciferase
and Renilla luciferase. All genes were targeted in a one-by-one
approach in an assay lasting ∼3 wk (Fig. S4A).
Fig. 2. H2b-GFPh MaSCs display a stem-like expression signature. (A) Sorting
strategy. We used a combination of four cell surface markers in addition to
H2b-GFP expression to segregate the lineage-depleted mammary gland cells
into six distinct cell types: H2b-GFPh MaSCs (Lin−CD24+CD29hH2b-GFPhCD61−),
myoepithelial progenitors cells (Lin-CD24+CD29hH2b-GFP−CD61+), myoepi-
thelial differentiated cells (Lin−CD24+CD29hH2b-GFP−CD61−), luminal pro-
genitor cells (Lin−CD24hCD29lCD61+CD133−), luminal ductal cells (Lin−CD24h
CD29lCD61−CD133+), and luminal alveolar cells (Lin−CD24hCD29lCD61−
CD133−). For each library, two biological replicates were analyzed. (B)
Mammary gland differential expression heat map. Clustering of RPKM
proﬁles for the 100 genes with highest variance across all samples. Two main
cell clusters were generated according to the expression patterns of ana-
lyzed genes: luminal- (progenitor, alveolar, and ductal cells) and basal-type
cells (H2b-GFPh MaSCs, progenitors, and differentiated cells). Note that H2b-
GFPh MaSCs cluster with other basal compartment cells but have an ex-
pression signature distinct from the other two cell types in this cluster.
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shRNAs were introduced into the immortalized mammary
gland cell line, Comma-Dβ (18). These cells give rise to both
luminal and myoepithelial compartments in colony-forming and
transplantation assays, independent of the method of MaSC
enrichment (19–21). In addition, ∼50% of Comma-Dβ cells stain
positive for Cd1d, placing them in our improved MaSCs isolation
proﬁle (Fig. S4B).
Cells were monitored for GFP expression (as a proxy for
shRNA expression), and changes in the proportion of GFP-
expressing cells would be indicative of a relevant gene function.
The majority of screened shRNAs did not alter GFP levels during
the 3-wk screening period (Fig. 4A), which could suggest that the
correspondent genes were not essential for growth maintenance
of Comma-Dβ cells. However, a distinct set of shRNAs altered
Fig. 3. Cd1d is an additional cell surface marker for puriﬁcation of MaSCs. (A) FACS analysis of MaSC cell surface markers. Total MaSCs (CD24+CD29h cells)
were additionally segregated according to the expression of the cell surface markers CD1d, CD59ah, or CD22. (B) CD1d is expressed by a subset of CD59ah cells.
Lin−mammary gland cells were stained with antibodies against CD24, CD29, CD1d, and CD59a and further analyzed on an LSRII Cell Analyzer (BD Bioscience).
The entire basal compartment (CD24+CD29h) was selected and analyzed according to CD1d and CD59a expression. The majority of cells within the basal
compartment stained positive for CD59a, and CD1d+ cells fell mainly in the CD59ah area. (C) CD1d MaSCs are the most label-retaining cells within the
mammary gland. Prepubescence mice were injected with BrdU (50 mg/kg body weight) for 5 d. Glands were either harvested from mice on the last day of
BrdU injection to evaluate the total BrdU incorporation (week 0) or harvested after a 12 wk BrdU chase. Single-cell suspensions were stained with antibodies
against CD24, CD29, and CD1d and analyzed on an LSRII Cell Analyzer (BD Bioscience). BrdU incorporation was measured in total MaSC (CD24+CD29h) and
CD1d MaSC (CD24+CD29hCD1d+) populations. (D and E) Histological analysis of mammary gland CD1d MaSCs outgrowths. Cleared fat pads from pre-
pubescent female mice were injected with (D) either total MaSCs or CD1d MaSCs and (E) 25 CD1d MaSCs cells harvested from glands pretransplanted with
CD1d MaSCs. Glands were harvested 12 wk after transplantation and embedded in agarose, and endogenous GFP signal was imaged. Images display out-
growths from two distinct glands injected with CD1d MaSCs cells (D) or secondary transplanted CD1d MaSCs (E).



















the maintenance of GFP-expressing cells by either depleting
GFP+ cells (Fig. 4A, lethal shRNAs) or promoting expansion of
GFP+ cells (Fig. 4A, survival shRNAs) over time.
We decided to further investigate a subset of genes that in-
terfered with Comma-Dβ growth, because our focus was to un-
derstand the spectrum of genes that might block normal
mammary gland biogenesis. Among the selected genes were
mucin-like gene (Muc4), G protein-coupled receptor gene family
member (Grk4), and transcription factors (MafK and Sltm). An
additional set of hairpins for these genes was rescreened in
Comma-Dβ cells with GFP levels followed for 10 d. No clear
effect on the percentage of GFP-positive cells was observed
when cells expressed the new shRNAs against Muc4 and Renilla
luciferase control, whereas an shRNA-dependent response was
observed, according to GFP frequency, when the genes Grk4 and
Mafk were targeted (Fig. 4B). In addition, both new shRNAs
against the gene Sltm consistently decreased GFP-expressing
cells to levels comparable with the depletion achieved by Rpa3,
the lethal control. Interestingly, Sltm encodes a transcription
factor-like protein that binds both DNA (scaffold attachment
factor-box DNA binding motif) and RNA (RNA binding do-
main) in response to estrogen levels (22). We are currently
investigating the implications caused by loss of Sltm expression
during normal mammary gland development and tumorigenesis.
Discussion
The ongoing interest in stem cells and more recently, cancer
stem cells highlights the need for improvements in puriﬁcation
and analysis of this rare but important population. Our previous
understanding of MaSCs has been clouded by the limited
capability to obtain a pure population devoid of contaminating,
more differentiated cells. Here, we took advantage of a pre-
viously used system to identify relatively quiescent cells (6) in the
mammary gland. We propose that the label-retaining cells from the
K5tTa-H2b-GFP mouse represent a subset of active MaSCs,
displaying increased mammary gland reconstitution ability over
previously published cell populations identiﬁed as MaSCs.
Unlike previous methods, where cell selection is based on the
presence of constitutive ﬂuorescence in cells (3, 23), the use of
a cell state-dependent GFP system allows for a more biological
relevant ﬂuorescence reliability. The extended time between
halting GFP expression and analysis and also, selection of only
the brightest cells decrease the possibility that the GFP protein
might be detected in a cell cycling at a normal rate, despite the
fact that the GFP expression is switched off. This system allowed
for the possibility of a much more stringent selection process;
however, it is acknowledged that there are limitations with using
this mouse model on a routine basis for enriching for MaSCs.
The need to use a transgenic mouse and however reduced, the
level of heterogeneity within cells selected—evident by <100%
regrowth efﬁciency—illustrate the need for the cell surface
marker, CD1d, identiﬁed in our study.
Cd1d is known to be expressed as a cell surface marker on
a variety of antigen-presenting cells belonging to a cluster of
glycoproteins involved in T-cell antigen presentation (13). Be-
cause we physically remove all hematopoietic cells using mag-
netic beads before FACS, we are conﬁdent that this differentially
expressed marker does not simply reﬂect contaminating cells.
This statement is supported by the presence of CD1d+ cells
within the normal-like mammary gland cell line, Comma-1Dβ. In
fact, 50% of these cells, isolated during midpregnancy, were
positive for CD1d when stained with two distinct antibodies
(Fig. S4B).
We, therefore, propose that CD1d is a genuine marker for
MaSCs and when used combined with the cell surface markers
CD24 and CD29, greatly enhances the puriﬁcation of recon-
stituting cells above and beyond those cells selected based on
label retention alone and those selected based on previously
published markers. We perhaps did not exhaust all of the pos-
sibilities presented by our RNAseq data for the description of
novel MaSC markers, but our ﬁndings do support CD1d as being
a valuable component for purifying true MaSCs.
We found the proportion of CD1d+ cells (1%) within the basal
compartment to be greater than the proportion ofH2b-GFPh cells
(0.2%) in this same compartment. This observation draws to light
another drawback of relying solely on this particular label-
retaining mouse model and in the same context, relying on GFP
expression of a gene reporter mouse to identify MaSCs. The
cytokeratin K5 (Krt5), for example, although shown to be
expressed by basal-type cells, may not be expressed by all cells in
this compartment. In addition, GFP expression may also be dis-
rupted in some cells, perhaps by suppression of the transgene
promoter; alternatively, some cells could fail to shut down GFP
expression on DOX treatment. Had we only selected cells based
on GFP expression from the K5 promoter, we would not be
selecting all—or solely—those cells capable of self-renewal. This
exclusion of MaSCs has been illustrated previously, where cells
negative for a reporter GFP were able to still proliferate and re-
generate into a new gland (3), something that we also see to
a small degree with the K5tTa-H2b-GFP mouse model.
The identiﬁcation of CD1d as a unique marker for this MaSC
population and the distinct transcriptome of the Cd1d MaSCs
suggest that these cells perform a function distinct from pro-
genitors and more differentiated cells. Despite their gene ex-
pression proﬁle clustering more closely with myoepithelial cells,
they are still able to produce a new gland. It is unclear, however,
if all of the CD1d MaSCs are multipotent stem cells or if they
represent a combination of the recently described luminal and
Fig. 4. Mammary gland focused screen. (A) One by one screen; 206 shRNAs,
covering ∼56 genes, were tested. The solid line square shows the fold
change of shRNAs considered to be lethal, because GFP percent for these
cells decreased overtime, whereas the dashed line square highlights data
from shRNAs considered to show survival preferences in cells, because GFP
percent increased overtime. (B) Screen hits validation. Two new hairpins
targeting four genes selected as lethal hits from the ﬁrst screen. The chart
represents results of two independent experiments. *P = 0.05 by the t test.
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myoepithelial unipotent MaSCs (23). Because we are not using
lineage tracing here, we cannot say for certain if all of the
injected CD1d MaSCs would give rise to both compartments
when allowed to repopulate the gland and if they are them-
selves the precursors to the cells that are largely responsible for
tissue maintenance.
Identifying the genes involved in maintaining a stem cell and
their self-renewing capabilities is vital to furthering our un-
derstanding of how these genes might be involved in abnormal
gland development and tumorigenesis. Our current knowledge
on this hypothesis, however, is, at best, limited; until now, it has
been difﬁcult to segregate myoepithelial cells and MaSCs, be-
cause they share common cell surface markers and very similar
gene expression proﬁles (1, 24). The large number of shared
genes expressed among cells identiﬁed by standard markers
would mask any true differential patterns expressed by those
cells with self-renewing properties. CD1d MaSCs cells only be-
come divergent when the expression patterns of a relatively small
number of genes are considered, a fact that would be overlooked
if not using a more reﬁned selection process. In addition to
improving gene proﬁling as a whole for this minority population,
the use of CD1d to isolate single cells for proﬁling could provide
clues to gene expression changes between hypothesized MaSC
states. For example, the complete loss of label-retaining cells
after pregnancy suggests that these cells have undergone a more
extensive process of cell division than in a virgin gland. However,
CD1d+ cells are still present, unaltered to some extent, and using
this marker, it would be possible to monitor gene expression
changes during pregnancy and involution.
It has been suggested that stem cells within the mammary gland
contribute in some way to the proposed notion of a cancer stem
cell. In mouse mammary tumor virus (MMTV)-Wnt1 and p53−/−
mice, for example, a preneoplastic mammary gland was seen to
have an increased number of functional MaSCs, and ectopic ex-
pression of wnt-1 enhanced the self-renewing capabilities of cells,
leading to cancers (24). CD1d itself has even been linked to breast
cancer. In one study, antibodies against CD1d, combined with anti
death receptor 5 (anti-DR5), a TNF-related apoptosis inducing
ligand (TRAIL) receptor, led to rejection of tumor growth after
injection of 4T1 tumor cells, a mouse breast cancer cell line (25),
into a syngeneic mouse fat pad (26). Whether this observation was
a result of the proposed interaction with natural killer cells or
a disruption of the ability of the cancer to self-renew remains to be
seen. The latter could be possible, because we show that the 4T1
mouse breast cancer cell line (Fig. S4C) and primary mouse breast
cells (27) (Fig. S4D) display a population of cells that is positive
for Cd1d. In humans as well, CD1d plays some unknown role.
Down-regulation of CD1d expression has been shown to correlate
with increasing metastasis in a mouse breast cancer model (28)
and disease progression in multiple myeloma (29). Our own
studies have shown that CD1d is expressed as a cell surface
marker in some but not all of the human breast cancer cell lines
tested (Fig. S4E). Those cell lines that showed CD1d+ cells were
from basal-like breast cancers; luminal-like cancer cell lines,
however, showed no CD1d+ cells.
With the ability to now purify a more homogeneous self-
renewing population of MaSCs, it is possible to delve more deeply
into the biology of these cells. We have not only appointed CD1d
as a marker of MaSCs but also used this information to draw out
gene targets for disrupting mammary gland development and
possibly, malignancies. It is also unknown yet if these speciﬁc cell
markers are a cause or effect of the ability of the cell to retain
stemness; interrupting their expression and studying the effect on
gland development and cancer are critical topics of future study.
Materials and Methods
Mice. K5tTa-H2b-GFP heterozygote mice (6) were bred, and 20-d-old pups
were checked for GFP expression using the IVIS100 in vivo imaging system
(Caliper). CD-1 female mice were purchased from Charles River. Basal-like
mouse mammary gland tumors were obtained from the transgenic mouse
mammary tumor model C3-tag (27) (a gift from Mikala Egeblad, Cold Spring
Harbor Laboratory, New York). All experiments were performed in agree-
ment with and approved by the Cold Spring Harbor Laboratory Institutional
Animal Care and Use Committee.
Two-Photon Microscopy. Mammary glands were harvested and defatted by
three rounds of acetone treatment (20 min each). Defatted mammary glands
were embedded and imaged according to previously published methods (30).
In short, experiments were performed on a high-speed multiphoton micro-
scope with integrated vibratome sectioning (TissueCyte 1000; TissueVision,
Inc.). 3D scanning of 5-mm Z-volume stacks was achieved with a microscope
objective piezo (PI E-665 LVPZT ampliﬁer and P-725 PIFOC long-travel ob-
jective scanner), which translated the microscope objective with respect to
the sample. Each optical section was imaged as a mosaic of individual ﬁelds
of view equal to 0.83 × 0.83 mm and reconstructed posthoc using Fiji and
custom-written Matlab software.
Antibodies. Antibodies for ﬂow cytometry were purchased from eBioscience
unless otherwise speciﬁed, and they include anti-CD24 eFluor@ 450, bio-
tinylated and PE-conjugated anti-CD45, biotinylated and phycoerythrin
(PE)-conjugated anti-CD31, biotinylated and PE-conjugated anti-Ter119, PE-
Cy7–conjugated anti-CD29, FITC- and PE-conjugated anti-CD61, antigen-
presenting cell-conjugated anti-CD133, PerCP-CY5.5– and PE-conjugated
anti-Cd1d (clones 1B1 and K253, respectively; BioLegend), PE-conjugated
anti-CD22, monoclonal CD59a (Hycult Biotech), PE-conjugated human anti-
Cd1d, 7-AAD viability staining solution (BioLegend), FITC-conjugated mouse
IgG, and PE-conjugated rabbit IgG. Antibodies for immunostaining were
chicken anti-GFP (Invitrogen), mouse monoclonal Cytokeratin 18 (SCTB), anti-
chicken–IgG-Alexa Fluor 647 (Invitrogen), and anti-mouse–IgG Alexa Fluor 568
(Invitrogen).
Mammary Gland Preparation. Mammary glands were harvested from young
female mice (6–10 wk) and dissociated according to previously published
protocol (1). After dissociation, cells were resuspended in 1 mL MACS Buffer
(Myltenyi Biotech) and incubated with biotinylated anti-CD45, anti-Ter119,
and anti-CD31 antibodies for 20 min. Cells were washed with 10 volumes
MACS Buffer and further incubated with antibiotin magnetic microbeads
(Myltenyi Biotech). Labeled cells were loaded into a magnetic column at-
tached to a magnetic ﬁeld (Myltenyi Biotech), and lineage-depleted ﬂow-
through cells were collected and further stained.
Flow Cytometry. Cells were stained for 30 min at 4 °C with antibody mix in PBS
supplemented with 1% (vol/vol) FBS followed by wash with 10× volume PBS.
Cells were resuspended in PBS plus 1% (vol/vol) FBS and further stained with
7-AAD immediately before sorting or analysis. Cells were sorted using a FACS
ARIAII SORP (BD Bioscience). For cell analysis, LRSII (BD Bioscience) cell an-
alyzer or MACSQuant (Myltenyi Biotech) were used. Data analysis was per-
formed using either FloJo (Tree Star) or Diva (BD Bioscience).
Matrigel Colony Assay. Cells were sorted into 96-well plates containing 100 μL
chilled 50% (vol/vol) Matrigel Matrix (BD Bioscience), further transferred to
100% Matrigel Precoated Chamber Slides (Lab-Tek), and incubated at 37 °C
for 5 min. Complete Growth Media (1) was added to the chamber and
renewed every other day for 10 d. Colonies were counted using Nikon
Eclipse T1 microscope (Nikon).
Mammary Gland Transplant. Cells were sorted into 96-well plates containing
30 μL 50% (vol/vol) Growth Factor Reduced Matrigel (BD Bioscience) and
0.01% (vol/vol) Tripan Blue (Sigma). Cells were injected into inguinal glands
of 3-wk-old females that had been cleared of endogenous epithelium. Re-
cipient glands were removed for evaluation 8–12 wk after cell injection.
Mammary Transplant Analysis. Frozen sections and/or agarose-embedded
sections were ﬁxed with 4% paraformaldehyde (Sigma) for 20 min followed
by tissue permeabilization and blocking using 10% (vol/vol) goat serum
(Sigma). Parafﬁn-embedded sections were dewaxed and subjected to antigen
retrieval for 15 min in Trilogy buffer (Cell Marque) before blocking as de-
scribed above. Primary antibody staining was performed overnight at 4 °C
with constant agitation followed by three washes with 0.1% (vol/vol) Tween
20. Secondary antibody staining was carried out for 45 min at room tem-
perature with constant agitation followed by three washes with 0.1% (vol/
vol) Tween 20. Slides were mounted with ProLong Gold supplemented with



















DAPI (Invitrogen). For immunohistochemistry detection of GFP-positive
outgrowths, the kit Ace IHC Detection Kit (Epitomics) was used according to
the manufacturer’s instructions. Tissue sections were analyzed using either
the Nikon Eclipse T1 microscope (Nikon) or Zeiss LSM 710 confocal micro-
scope. For whole-mount images, glands were harvested, spread atop a glass
slide, defatted, and stained with Carmine Aluminum solution prior image
analysis. MRU frequency was estimated using the ELDA algorithm (10).
Mammary gland reconstitution was considered successful if, by the time
of analysis, at least one-third of the fat pad was repopulated with GFP+
structures.
RNAseq Library Preparation. Cells were sorted into Eppendorf tubesﬁlled with
TRIzol LS (Invitrogen), and RNA puriﬁcation was performed according to
the manufacturer’s instructions. DNase-free RNA samples were used for the
preparation of double-strand cDNA libraries using the Version 1 Ovation
RNAseq System (Nugen). cDNA libraries were phosphorylated, adenylated,
and ligated to Illumina adapters followed by PCR enrichment. Single-ended
sequencing was performed for 36 cycles in Illumina GAII instruments (Illumina).
RNAseq Mapping and Analysis. We used the Refseq transcriptome (mm9
mouse assembly) downloaded through the University of California, Santa
Cruz (USCS) Table Browser (31). Reads were mapped in two stages: ﬁrst, they
were mapped to sequences constructed using all annotated Refseq exons
with overlapping exons collapsed, and second, they were mapped to all
possible junctions formed from all pairs of exons for the same gene. Map-
ping was done with RMAP (32) and allowed up to three mismatches in 36
bases. Reads mapping ambiguously (including mapping to an exon and
a junction) were discarded. For each Refseq transcript, we counted the
number of reads with mapping location that was inside the transcript’s
exons (allowing a given read to be counted for two distinct transcripts as
long as the location is unique) or through one of the transcript’s junctions.
Reads per kilobase per million (RPKM) calculations discarded duplicate reads
and corrected gene size for the portion of the gene that cannot be uniquely
mapped. Differential expression between two RNAseq experiments was
computed using a 2 × 2 contingency table and either a χ2 statistic or Fisher
exact test to obtain a P value for differential expression. Brieﬂy, the con-
tingency tables contained, for each gene, the counts of reads mapping into
the gene and the counts of reads mapping outside the gene for both
experiments. The P values were corrected for multiple testing using the
Bonferroni correction. The genes that remained were called as differentially
expressed (corrected P > 0.01), and rankings for differentially expressed
genes were based on ratios of RPKM values.
Quantitative PCR. Cells were sorted into 96-well plates containing 30 μL Cell-
To-Ct lysis buffer (Ambion). cDNA synthesis was performed according to the
manufacturer’s instruction. Real-time PCR was performed using speciﬁc
Taqman probes (Applied Biosystems) for each gene and Gapdh mRNA as an
endogenous control. Samples were run on a 7900 Real-Time PCR System
(Applied Biosystems).
BrdU Experiment. BrdU label-retaining experiments were performed using the
BrdU-APC Flow Kit (BD Bioscience); 3-wk-old female mice were injected with
BrdU (one time per day for 5 consecutive d, 50 mg/kg body weight), and
mammary glands were harvest at speciﬁed time points. Mammary gland cells
were prepared according to the BrdU manufacturer’s recommendations.
Cells were analyzed with an LSRII Cell Analyzer (BD Bioscience), and 1 million
cells were recorded per sample. For each experiment (n = 2), three glands
were analyzed at week 0 (last day of BrdU injection), and three glands were
analyzed at week 12 after BrdU injection.
Knockdown Experiment. shRNAs against 56 selected genes were pulled and
transferred frompGIPz (LMN vector) lentiviral backbone (Open Biosystems) to
MSCV-miR30-PGK-NEO-IRES-GFP retroviral backbone (a gift from Christopher
R. Vakoc, Cold Spring Harbor Laboratory, New York). Plasmid was transfected
into Plat-E cells (33) using Lipofectamine 2000 and vesicular stomatitis virus
g-protein (VSVG), and virus was collected 24 and 36 h posttransfection. Cells
were infected by spin infection and allowed 2 d for recovery. GFP levels were
measured using MACSQuant Cell analyzer (Miltenyi Biotech) from 10,000
cells. Hairpins used on validation experiments were ordered as oligonucleo-
tides from Integrated DNA Technologies (IDT) and used as the template for
PCR reactions using KOD hot-start polymerase (EMDMilipore) and the primers
5MIR (5′-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3′) and
3MIR (5′-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3′). PCR products
were column-puriﬁed (Qiagen), digested with EcoRI and XhoI enzymes, and
cloned into predigested LMN vectors using T4 rapid ligase (Promega).
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